Kestra Medical Technologies, Ltd. (KMTS) Stock Score, Valuation & Financial Research
Kestra Medical Technologies, Ltd. is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 29/100.
Quick answer for KMTS
Kestra Medical Technologies, Ltd. currently has a Wall Street Score of 29/100. The stored market price is $23.33. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Kestra Medical Technologies, Ltd. does
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement
KMTS financial snapshot
- Wall Street Score:
- 29/100
- Current price:
- $23.33
- Market capitalization:
- $1.37B
- Revenue:
- $95.1M
- Net income:
- $-131.6M
- Free cash flow:
- $-116.6M
- Cash:
- $99.7M
- Total debt:
- $4.1M
- EPS:
- -2.43
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-116.6M, showing cash burn in the current stored period.
- The balance sheet shows $99.7M of cash versus $4.1M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research KMTS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.